Marshall Wace
DWTX

Marshall Wace’s Dogwood Therapeutics DWTX Stock Holding History

Marshall Wace’s Portfolio DWTX Stock Details DWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24.8K Buy
11,756
+101
+0.9% +$297 ﹤0.01% 3035
2025
Q4 		$48.5K Buy
+11,655
New +$68.6K ﹤0.01% 2780

Other funds holding DWTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace's DWTX Position: Q1 2026 in Review

Marshall Wace increased its Dogwood Therapeutics (DWTX) stake by 0.87% in Q1 2026, buying an estimated $297 and bringing the position to 11,756 shares worth $24.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3035.

Marshall Wace first reported a position in DWTX in Q4 2025 and has held it in 2 quarters since. The position peaked at $48.5K in Q4 2025. 13 funds tracked by Wall St. Rank hold DWTX as of Q1 2026.

  • Marshall Wace held 11,756 shares of Dogwood Therapeutics worth $24.8K as of Q1 2026.
  • Marshall Wace bought 101 Dogwood Therapeutics shares in Q1 2026, an estimated $297.
  • Dogwood Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #3035 holding.
  • Marshall Wace first reported a position in Dogwood Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Marshall Wace's Dogwood Therapeutics position peaked at $48.5K in Q4 2025.
  • 13 funds tracked by Wall St. Rank held Dogwood Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.